Amgen reported FY2025 revenue of $36.75 billion and Q1 2026 revenue of $8.62 billion, with the official record tying the thesis to biologics scale, acquired-product integration, patent cliffs, pipeline execution, leverage and cash conversion.
References
Sources used in this report
SEC datasetSEC company tickers exchange datasetRetrieved 2026-05-19 · Issuer identity, ticker, exchange and CIKSEC APISEC submissions APIRetrieved 2026-05-19 · Filing chronology and company identitySEC XBRL APISEC companyfacts APIRetrieved 2026-05-19 · Financial statement cross-checksAnnual reportFY2025 Form 10-K filed 2026-02-132026-02-13 · Annual business, risk and financial baselineQuarterly reportForm 10-Q filed 2026-05-012026-05-01 · Latest interim financial baselineCurrent reportForm 8-K filed 2026-05-192026-05-19 · Recent filing chronology and earnings contextProxy statementDEF 14A filed 2026-04-072026-04-07 · Governance and incentive context